Published in J Addict Med on August 06, 2013
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ (2015) 2.38
Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res (2014) 0.98
Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz et al. (2017) Article. Alcohol Clin Exp Res (2017) 0.97
Substance abuse among older adults. Clin Geriatr Med (2014) 0.93
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology (2016) 0.90
Cognitive control in alcohol use disorder: deficits and clinical relevance. Rev Neurosci (2014) 0.89
MiR-153 targets the nuclear factor-1 family and protects against teratogenic effects of ethanol exposure in fetal neural stem cells. Biol Open (2014) 0.89
Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. Br J Pharmacol (2014) 0.87
The role of varenicline on alcohol-primed self-administration and seeking behavior in rats. Psychopharmacology (Berl) (2015) 0.86
Pharmacological approaches to reducing craving in patients with alcohol use disorders. CNS Drugs (2014) 0.86
Nicotinic receptor modulation to treat alcohol and drug dependence. Front Neurosci (2015) 0.85
Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl) (2014) 0.85
Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption. PLoS One (2013) 0.84
Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. Neuropsychopharmacology (2015) 0.82
Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food. Alcohol Clin Exp Res (2014) 0.81
Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol (2016) 0.80
A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology (Berl) (2014) 0.80
A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration. Sci Rep (2016) 0.79
Substance use in older HIV-infected patients. Curr Opin HIV AIDS (2014) 0.79
Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis. J Addict Med (2015) 0.79
"Killing Two Birds with One Stone": Alcohol Use Reduction Interventions with Potential Efficacy in Enhancing Self-Control. Curr Addict Rep (2014) 0.79
Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. J Addict Med (2016) 0.78
Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine. Neuropsychopharmacology (2015) 0.78
Varenicline Reduces Context-Induced Relapse to Alcohol-Seeking through Actions in the Nucleus Accumbens. Neuropsychopharmacology (2016) 0.77
Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. CNS Drugs (2015) 0.77
Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers. Curr Addict Rep (2016) 0.77
Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse. Behav Brain Res (2015) 0.77
Translating Alcohol Research: Opportunities and Challenges. Alcohol Res (2015) 0.76
Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry (2015) 0.76
The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats. Addict Biol (2015) 0.76
Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. Drug Alcohol Depend (2015) 0.76
Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization. Alcohol Clin Exp Res (2014) 0.76
Management of Alcohol Use Disorder in Patients Requiring Liver Transplant. Am J Psychiatry (2015) 0.76
Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clin Exp Res (2016) 0.76
Drug effects on multiple and concurrent schedules of ethanol- and food-maintained behaviour: context-dependent selectivity. Br J Pharmacol (2014) 0.76
Preclinical Medication Development: New Targets and New Drugs. Alcohol Clin Exp Res (2016) 0.75
Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. Curr Addict Rep (2014) 0.75
Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. Alcohol Clin Exp Res (2016) 0.75
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.75
A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking. Alcohol Clin Exp Res (2017) 0.75
Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis. Addict Disord Their Treat (2015) 0.75
An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder. Contemp Clin Trials (2016) 0.75
Mechanisms underlying sleep-wake disturbances in alcoholism: focus on the cholinergic pedunculopontine tegmentum. Behav Brain Res (2014) 0.75
Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers. Int J Neuropsychopharmacol (2015) 0.75
Automatic Avoidance Tendencies for Alcohol Cues Predict Drinking After Detoxification Treatment in Alcohol Dependence. Psychol Addict Behav (2016) 0.75
Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology (2017) 0.75
Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats. Alcohol Clin Exp Res (2017) 0.75
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict (1991) 63.91
A power primer. Psychol Bull (1992) 63.66
A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol (1996) 20.25
Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet (2009) 16.12
The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend (2004) 13.53
Addiction and dependence in DSM-V. Addiction (2010) 13.28
Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA (2007) 6.81
Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med (2011) 6.52
The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction (2010) 5.14
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol (2006) 3.84
Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res (1999) 3.63
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A (2007) 2.68
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction (2012) 2.64
Helping patients who drink too much: an evidence-based guide for primary care clinicians. Am Fam Physician (2009) 2.27
Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry (2009) 2.25
Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol (2012) 1.56
Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res (2000) 1.43
Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) (2012) 1.41
Epidemiology and alcohol policy in Europe. Addiction (2011) 1.39
Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology (2010) 1.37
Alcohol's actions on neuronal nicotinic acetylcholine receptors. Alcohol Res Health (2006) 1.33
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) (2011) 1.31
Co-occurring risk factors for alcohol dependence and habitual smoking: update on findings from the Collaborative Study on the Genetics of Alcoholism. Alcohol Res Health (2006) 1.27
A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) (2011) 1.27
The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther (2009) 1.25
Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol Clin Exp Res (2002) 1.25
The genetic components of alcohol and nicotine co-addiction: from genes to behavior. Curr Drug Abuse Rev (2008) 1.25
Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. Psychopharmacology (Berl) (2007) 1.24
Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res (2002) 1.16
Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res (2011) 1.10
Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcohol Clin Exp Res (2005) 1.04
Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions. Front Mol Neurosci (2012) 1.04
Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology (Berl) (2007) 0.98
Lobeline and cytisine reduce voluntary ethanol drinking behavior in male C57BL/6J mice. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.93
Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacology (2009) 0.91
Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. Neurotox Res (2011) 0.88
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA (2006) 13.15
Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA (2007) 6.81
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A (2009) 6.09
Caffeinated energy drinks--a growing problem. Drug Alcohol Depend (2008) 4.98
Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res (2015) 4.94
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA (2005) 4.64
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry (2003) 3.85
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology (2005) 3.53
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol (2005) 2.98
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res (2010) 2.89
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology (2007) 2.73
Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS study. J Altern Complement Med (2010) 2.50
The status of disulfiram: a half of a century later. J Clin Psychopharmacol (2006) 2.48
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry (2003) 2.43
Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry (2002) 2.38
The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-month outcomes. Arch Gen Psychiatry (2005) 2.37
Buprenorphine: how to use it right. Drug Alcohol Depend (2003) 2.35
Concealment and fabrication by experienced research subjects. Clin Trials (2013) 2.31
A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry (2013) 2.29
A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend (2011) 2.05
Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry (2015) 2.03
Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat (2007) 1.99
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol (2005) 1.98
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain (2013) 1.89
Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders. Alcohol Clin Exp Res (2012) 1.84
The effectiveness of telephone-based continuing care in the clinical management of alcohol and cocaine use disorders: 12-month outcomes. J Consult Clin Psychol (2004) 1.82
Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry (2004) 1.70
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehabil J (2004) 1.66
A 3-year study of addiction mutual-help group participation following intensive outpatient treatment. Alcohol Clin Exp Res (2006) 1.61
Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals. Neuropsychopharmacology (2007) 1.57
Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol (2012) 1.56
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend (2009) 1.56
A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry (2013) 1.56
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med (2013) 1.54
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res (2005) 1.48
Yoga Asana sessions increase brain GABA levels: a pilot study. J Altern Complement Med (2007) 1.44
Debate: Clinical risk categorization is valuable in the prevention of suicide and severe violence? Yes. Australas Psychiatry (2014) 1.42
Tobacco use and mental illness: a wake-up call for psychiatrists. Psychiatr Serv (2014) 1.42
Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects. Neuropsychopharmacology (2007) 1.41
Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants. J Clin Psychiatry (2016) 1.39
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction (2013) 1.39
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc (2002) 1.37
Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. J Neurosci (2008) 1.37
Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry (2006) 1.34
Relation of depression diagnoses to 2-year outcomes in cocaine-dependent patients in a randomized continuing care study. Psychol Addict Behav (2002) 1.34
Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med (2008) 1.34
DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology (2008) 1.31
The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend (2009) 1.30
Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract (2005) 1.30
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend (2007) 1.28
Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol (2004) 1.25
Prevalence of violent victimisation in severe mental illness. Br J Psychiatry (2003) 1.25
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res (2006) 1.24
Characteristics of older opioid maintenance patients. J Subst Abuse Treat (2005) 1.22
Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol (2005) 1.20
HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat (2006) 1.17
Changing profile of abused substances by older persons entering treatment. J Nerv Ment Dis (2008) 1.16
Persistence of addictive disorders in a first-offender driving while impaired population. Arch Gen Psychiatry (2011) 1.15
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res (2008) 1.15
Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol (2005) 1.14
The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug Alcohol Depend (2011) 1.14
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord (2006) 1.13
Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study. Addict Behav (2008) 1.13
Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol (2006) 1.12
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat (2012) 1.10
Frontal lobe GABA levels in cocaine dependence: a two-dimensional, J-resolved magnetic resonance spectroscopy study. Psychiatry Res (2004) 1.10
A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol (2007) 1.10
Schizophrenia and co-occurring substance use disorder. Am J Psychiatry (2007) 1.09
Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys (2006) 1.08
Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. J Gen Intern Med (2002) 1.08
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res (2011) 1.08
The neural circuitry of reward and its relevance to psychiatric disorders. Curr Psychiatry Rep (2004) 1.07
Sleep deprivation impairs hippocampus-mediated contextual learning but not amygdala-mediated cued learning in rats. Eur J Neurosci (2004) 1.07
Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg (2013) 1.07
Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine (2011) 1.07